Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH013
Katarzyna Osiecka-Brzeska
Corporate social responsibility policies have become an important management strategy in companies. This sector tries to respond to stakeholders' needs while developing socially responsible business activities and sustainable values. A sustainable supply chain is an integral part of CSR strategy in a pharmaceutical industry. Purchased goods and services have to present high standards and quality. As international companies have many suppliers and contractors, it is important to conduct and promote worked out values among all business partners. The aim of this chapter is to investigate the corporate social responsibility values of Polpharma Group. The chapter describes the long-term strategy of sustainability in Polpharma and the responsibilities of Polpharma in all business sectors. The most essential part will be the description of the process of sustainable supply chain formation. The chapter will describe the implementation of a code of conduct among suppliers. The case study in this chapter will be based on Polpharma, one of the largest Polish pharmaceutical companies.
{"title":"Sustainable Supply Chain as a Part of CSR Strategy","authors":"Katarzyna Osiecka-Brzeska","doi":"10.4018/978-1-5225-5921-4.CH013","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH013","url":null,"abstract":"Corporate social responsibility policies have become an important management strategy in companies. This sector tries to respond to stakeholders' needs while developing socially responsible business activities and sustainable values. A sustainable supply chain is an integral part of CSR strategy in a pharmaceutical industry. Purchased goods and services have to present high standards and quality. As international companies have many suppliers and contractors, it is important to conduct and promote worked out values among all business partners. The aim of this chapter is to investigate the corporate social responsibility values of Polpharma Group. The chapter describes the long-term strategy of sustainability in Polpharma and the responsibilities of Polpharma in all business sectors. The most essential part will be the description of the process of sustainable supply chain formation. The chapter will describe the implementation of a code of conduct among suppliers. The case study in this chapter will be based on Polpharma, one of the largest Polish pharmaceutical companies.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127914676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH001
A. Szmelter
The objective of this chapter is to create an introduction to all subsequent chapters of the book. This is a description of basics of logistics and logistics management used in every part of the supply chain, in every sector of the regional economies and the global economy. The primary research question to be answered is: What is the role of logistics in creation of the supply chain's success? The answer will allow for presenting logistics as a main element of supply chain management in the current global economic ecosystem. It will be a guideline for the readers about how to think about logistics support for all discussed functional areas of supply chain management mentioned in the following parts of the book.
{"title":"Logistics Thinking","authors":"A. Szmelter","doi":"10.4018/978-1-5225-5921-4.CH001","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH001","url":null,"abstract":"The objective of this chapter is to create an introduction to all subsequent chapters of the book. This is a description of basics of logistics and logistics management used in every part of the supply chain, in every sector of the regional economies and the global economy. The primary research question to be answered is: What is the role of logistics in creation of the supply chain's success? The answer will allow for presenting logistics as a main element of supply chain management in the current global economic ecosystem. It will be a guideline for the readers about how to think about logistics support for all discussed functional areas of supply chain management mentioned in the following parts of the book.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130026498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH003
A. Szmelter
The pharmaceutical industry is seen as one of the most dynamic, volatile, and innovative parts of the global economic environment. It also has a big impact on the society and is an indicator of the healthcare systems' condition. Some changes have happened in the last decades, for example, shifting the production facilities to the developing countries, new market entries, or the new law changed the previously established and stable layout of market forces. The chapter aims at presenting the current situation of the global pharmaceutical industry including the main trends influencing the changes in this sector. Describing this part of the global market will ensure the right interpretation of the research results of the other parts of the book.
{"title":"Global Pharmaceutical Industry","authors":"A. Szmelter","doi":"10.4018/978-1-5225-5921-4.CH003","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH003","url":null,"abstract":"The pharmaceutical industry is seen as one of the most dynamic, volatile, and innovative parts of the global economic environment. It also has a big impact on the society and is an indicator of the healthcare systems' condition. Some changes have happened in the last decades, for example, shifting the production facilities to the developing countries, new market entries, or the new law changed the previously established and stable layout of market forces. The chapter aims at presenting the current situation of the global pharmaceutical industry including the main trends influencing the changes in this sector. Describing this part of the global market will ensure the right interpretation of the research results of the other parts of the book.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"730 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116067307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH012
A. Ganguly, D. Chatterjee, Asim Talukdar
The pharmaceutical supply chain is one of the most complex supply chains in the world. The primary objective of this chapter is to analyze the role of knowledge sharing barriers in supply chain performance. The chapter will explore significant knowledge sharing barriers that might deter the performance of a pharmaceutical supply chain. This chapter is expected to provide the twofold contribution to the academicians and practitioners. Firstly, it will socialize the importance of knowledge sharing barriers and the role they can play in deterring the performance of a pharmaceutical supply chain, and secondly, the prioritized ranking of the identified knowledge sharing barriers is expected to aid the policymakers and managers to understand the relative importance of the knowledge sharing barriers and design their knowledge management strategies accordingly.
{"title":"Knowledge Sharing Barriers Affecting Pharmaceutical Supply Chain Performance","authors":"A. Ganguly, D. Chatterjee, Asim Talukdar","doi":"10.4018/978-1-5225-5921-4.CH012","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH012","url":null,"abstract":"The pharmaceutical supply chain is one of the most complex supply chains in the world. The primary objective of this chapter is to analyze the role of knowledge sharing barriers in supply chain performance. The chapter will explore significant knowledge sharing barriers that might deter the performance of a pharmaceutical supply chain. This chapter is expected to provide the twofold contribution to the academicians and practitioners. Firstly, it will socialize the importance of knowledge sharing barriers and the role they can play in deterring the performance of a pharmaceutical supply chain, and secondly, the prioritized ranking of the identified knowledge sharing barriers is expected to aid the policymakers and managers to understand the relative importance of the knowledge sharing barriers and design their knowledge management strategies accordingly.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114888084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH002
Tharwa Najar, M. Amami
Since their initiation—characterized by an unsophisticated structure—organizations declare the necessity to organize, coordinate, and manage resources. This necessity is emphasized through the appearance of emergent types of structure assorted with crossing boundaries strategies (strategic alliances, virtual enterprise, modular enterprise, and so forth). This paradigm shift has a prevailing effect on the “way of doing” within organizations and networks. The chapter aims to expose the theoretical approaches that explain the formation and the dynamics of the supply chain (Section 1). As a second step, the notion of the supply chain management (Section 2) and the supply chain performance. It also presents the impact of the IOS use on supply chain performance (Section 3).
{"title":"Supply Chain and Inter-Organizational Information Systems Role","authors":"Tharwa Najar, M. Amami","doi":"10.4018/978-1-5225-5921-4.CH002","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH002","url":null,"abstract":"Since their initiation—characterized by an unsophisticated structure—organizations declare the necessity to organize, coordinate, and manage resources. This necessity is emphasized through the appearance of emergent types of structure assorted with crossing boundaries strategies (strategic alliances, virtual enterprise, modular enterprise, and so forth). This paradigm shift has a prevailing effect on the “way of doing” within organizations and networks. The chapter aims to expose the theoretical approaches that explain the formation and the dynamics of the supply chain (Section 1). As a second step, the notion of the supply chain management (Section 2) and the supply chain performance. It also presents the impact of the IOS use on supply chain performance (Section 3).","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117109150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH009
A. Saravanan
The pharmaceutical industry quite broadly encompasses a large and varied number of logistics and supply chain activities. The industry, as a whole, relies on some standard benchmarking indicators such as months of on-hand inventory and inventory turns; however, the existing metrics do not allow for idiosyncrasies of the industry or provide adequately detailed insight into the key factors that make a pharmaceutical supply chain excellence. Over 75% of the markup on pharmaceutical products takes place at the manufacturer. This causes inventory-carrying costs to increase dramatically once the distribution segments of the supply chain purchase the product. Wholesalers and large pharmacy chains suffer high carrying costs on the final product. Inside pharmaceutical supply chains, companies must also face issues of product expiration and limited shelf lives. Seasonal and short shelf life products such as flu vaccines leave companies without the opportunity to redistribute or reallocate product in order to meet demand.
{"title":"Pharmaceutical and Life Sciences Supply Chain Management","authors":"A. Saravanan","doi":"10.4018/978-1-5225-5921-4.CH009","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH009","url":null,"abstract":"The pharmaceutical industry quite broadly encompasses a large and varied number of logistics and supply chain activities. The industry, as a whole, relies on some standard benchmarking indicators such as months of on-hand inventory and inventory turns; however, the existing metrics do not allow for idiosyncrasies of the industry or provide adequately detailed insight into the key factors that make a pharmaceutical supply chain excellence. Over 75% of the markup on pharmaceutical products takes place at the manufacturer. This causes inventory-carrying costs to increase dramatically once the distribution segments of the supply chain purchase the product. Wholesalers and large pharmacy chains suffer high carrying costs on the final product. Inside pharmaceutical supply chains, companies must also face issues of product expiration and limited shelf lives. Seasonal and short shelf life products such as flu vaccines leave companies without the opportunity to redistribute or reallocate product in order to meet demand.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126820387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH010
E. Gunasundari
The pharmaceutical industry is under severe pressure due to complex supply chains that are underutilized, inefficient, and ill-equipped to cope with the sort of products. The pharma supply chain must meet the demands of a fast-evolving marketplace and the shift from patient to an outcome to undergo a radical overhaul. Research and development (R&D) costs in the pharma industry are spiraling, development timelines are growing, and consumers are becoming increasingly knowledgeable about care options including drugs and treatment. The marketplace is fixed through the development cycle and increasing efficiency through rationalization or outsourcing of non-core activities. Recently, the pharma industry moved from the “one-size-fits-all” approach for the supply chain flexibility, responsiveness, and reliability. This chapter enables readers to understand the techniques for rapid commission and decommission new products and markets and alternate supply models, inventory tracking tools to eliminate counterfeiting and parallel-importing risks.
{"title":"Best Practices in the Pharmaceutical Supply Chain Management","authors":"E. Gunasundari","doi":"10.4018/978-1-5225-5921-4.CH010","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH010","url":null,"abstract":"The pharmaceutical industry is under severe pressure due to complex supply chains that are underutilized, inefficient, and ill-equipped to cope with the sort of products. The pharma supply chain must meet the demands of a fast-evolving marketplace and the shift from patient to an outcome to undergo a radical overhaul. Research and development (R&D) costs in the pharma industry are spiraling, development timelines are growing, and consumers are becoming increasingly knowledgeable about care options including drugs and treatment. The marketplace is fixed through the development cycle and increasing efficiency through rationalization or outsourcing of non-core activities. Recently, the pharma industry moved from the “one-size-fits-all” approach for the supply chain flexibility, responsiveness, and reliability. This chapter enables readers to understand the techniques for rapid commission and decommission new products and markets and alternate supply models, inventory tracking tools to eliminate counterfeiting and parallel-importing risks.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124691675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH007
S. Ponnusamy, F. Christopher
The most important stress related to the industrialized societies are diseases and health issues caused by taking medicines that are in unfavorable condition. The health issues caused due to the medications mainly depend on the quality of drugs. This is the main test confronted by any pharmaceutical organization wishing to guarantee its survival. The benefit in the pharmaceutical industries is higher. But now, the cost of the medicines is reduced as per the estimation is given by the government. Hence, pharmaceutical organizations now confront a moment of challenge to diminish costs through upgrading and enhancing their production methods. Based on the production process following in the pharmaceutical industries, the product quality can be varied and improved. This chapter prescribes the detailed information regarding the production practices that are followed in the pharmaceutical industries for the production of high-quality products.
{"title":"Production Process in the Pharmaceutical Industry","authors":"S. Ponnusamy, F. Christopher","doi":"10.4018/978-1-5225-5921-4.CH007","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH007","url":null,"abstract":"The most important stress related to the industrialized societies are diseases and health issues caused by taking medicines that are in unfavorable condition. The health issues caused due to the medications mainly depend on the quality of drugs. This is the main test confronted by any pharmaceutical organization wishing to guarantee its survival. The benefit in the pharmaceutical industries is higher. But now, the cost of the medicines is reduced as per the estimation is given by the government. Hence, pharmaceutical organizations now confront a moment of challenge to diminish costs through upgrading and enhancing their production methods. Based on the production process following in the pharmaceutical industries, the product quality can be varied and improved. This chapter prescribes the detailed information regarding the production practices that are followed in the pharmaceutical industries for the production of high-quality products.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127886267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH006
Yaashikaa Ponnambalam Ragini
The most significant attribute of the pharmaceutical industry is its creations and advancements. The innovation of new drugs is necessary for improving the quality of human life and duration. Pharmaceutical drug development is a time-consuming, costly, and crucial process. The essential goal of drug development is to discover a dosage or dosage scale of a drug application that is both efficient in curing the desired disease and safe. Clinical trials including newly developed drugs that are directed in a progression of successive steps called stages to decide the security and efficacy of the new drug moreover the viability against the targeted diseases. There are four phases through which clinical trials are conducted. An investigational item can be assessed in more than one stage all the while in various clinical trials, and some clinical trials may cover two unique stages.
{"title":"Pharmaceutical Development Process","authors":"Yaashikaa Ponnambalam Ragini","doi":"10.4018/978-1-5225-5921-4.CH006","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH006","url":null,"abstract":"The most significant attribute of the pharmaceutical industry is its creations and advancements. The innovation of new drugs is necessary for improving the quality of human life and duration. Pharmaceutical drug development is a time-consuming, costly, and crucial process. The essential goal of drug development is to discover a dosage or dosage scale of a drug application that is both efficient in curing the desired disease and safe. Clinical trials including newly developed drugs that are directed in a progression of successive steps called stages to decide the security and efficacy of the new drug moreover the viability against the targeted diseases. There are four phases through which clinical trials are conducted. An investigational item can be assessed in more than one stage all the while in various clinical trials, and some clinical trials may cover two unique stages.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129295395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH004
S. Suganya
The pharmaceutical industry is trending in business decisions to demonstrate financial impact, influence on the behavior of consumers, governments, and businesses. This impact is beyond geographies and industries. It must be understood how a trend's impact will manifest itself in an actionable business planning horizon. Most of the pharmaceutical industries believe that global trends will shape business decisions over the next 5 to 10 years. Each management team in the pharmaceutical industry works on the global forces shaping their strategic context. The collisions approach is a systematic way to capture trends in strategy that enables your leadership team to rapidly combine multiple trends, facts, and perspectives to identify the “market-shaping force” that has the power to significantly shift spending and profit pools. This chapter discusses the effective competition in the pharmaceutical industry in the implementation of new technologies and trends to contribute to broader solutions.
{"title":"Global Macrotrends in Pharmaceutical Industry","authors":"S. Suganya","doi":"10.4018/978-1-5225-5921-4.CH004","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH004","url":null,"abstract":"The pharmaceutical industry is trending in business decisions to demonstrate financial impact, influence on the behavior of consumers, governments, and businesses. This impact is beyond geographies and industries. It must be understood how a trend's impact will manifest itself in an actionable business planning horizon. Most of the pharmaceutical industries believe that global trends will shape business decisions over the next 5 to 10 years. Each management team in the pharmaceutical industry works on the global forces shaping their strategic context. The collisions approach is a systematic way to capture trends in strategy that enables your leadership team to rapidly combine multiple trends, facts, and perspectives to identify the “market-shaping force” that has the power to significantly shift spending and profit pools. This chapter discusses the effective competition in the pharmaceutical industry in the implementation of new technologies and trends to contribute to broader solutions.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122299272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：